Core Viewpoint - JPMorgan has increased its stake in Tiger Medical (03347) by acquiring 501,547 shares at a price of HKD 38.9488 per share, totaling approximately HKD 19.5347 million, resulting in a new holding of about 10.3405 million shares, representing 8.39% of the company [1] Group 1 - JPMorgan's recent acquisition of shares indicates a bullish sentiment towards Tiger Medical [1] - The total investment made by JPMorgan in this transaction is approximately HKD 19.5347 million [1] - After the increase, JPMorgan's total shareholding in Tiger Medical stands at approximately 10.3405 million shares [1]

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Group 1 - The CRO concept stocks are experiencing a collective rebound, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 2.73% as of November 24, 2025 [1] - Notable individual stock performances include Tigermed (03347) increasing over 9%, and other companies like Hansoh Pharmaceutical (03692), MicroPort Medical (00853), and WuXi AppTec (02359) also seeing gains [1][2] - The Hong Kong Medical ETF (159366) has risen over 2%, and over the past six months, it has accumulated a 29.35% increase [1][2] Group 2 - The innovative drug industry is benefiting from dual advantages of policy support and explosive demand, which are activating new drug research and development needs, positively impacting the CXO sector [3] - Among 29 listed companies in the A-share CXO sector, 20 reported year-on-year revenue growth in the first three quarters, indicating strong industry resilience [3] - WuXi AppTec's unique "integrated, end-to-end" CRDMO business model has driven steady growth, with total revenue of 32.86 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.6%, and net profit attributable to shareholders rising by 84.8% to 12.08 billion yuan [3] Group 3 - The high growth of the CXO sector is supported by the trend of pharmaceutical companies outsourcing R&D and production to specialized CXO firms, which helps reduce costs and improve efficiency [4] - CXO companies are enhancing their service capabilities through continuous technological development and scale expansion, leading to deeper integration with pharmaceutical companies [4] - As of October 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index accounted for 62.83% of the index, indicating a high concentration in the market [4]

Core Viewpoint - Tiger Med's stock price has experienced a decline of 6.87% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the market despite a recent uptick in share price [1][2]. Group 1: Stock Performance - On November 24, Tiger Med's stock rose by 2.02%, reaching 50.59 CNY per share, with a trading volume of 169 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 43.559 billion CNY [1]. - Year-to-date, the stock has decreased by 6.87%, with a drop of 8.98% over the last five trading days, 5.21% over the last 20 days, and 23.83% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The largest shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares to 48.3625 million shares, and other notable shareholders such as China Europe Medical Health Mixed A and Huabao Zhongzheng Medical ETF [3].

Tigermed (3347.HK) Conference Call Summary Company Overview - **Company**: Tigermed (3347.HK) - **Market Cap**: HK$33.1 billion / $4.3 billion - **Industry**: China & Korea Healthcare Services - **Current Price**: HK$38.32 - **12-Month Price Target**: HK$63.40 (Upside: 65.4%) [1] Key Points Industry and Market Context - The biotech sector presents a structural growth opportunity, supported by global R&D alignment and industry consolidation [3][18] - Domestic biotechs have not yet increased spending in clinical trials, but Tigermed's clinical registration business has begun to recover, showing a 20% year-over-year growth [2] Financial Performance - **3Q Results**: The stock initially rallied post-results due to stronger-than-expected investment income and steady order growth, but later retraced to previous levels [1] - **New Orders**: Grew at a mid-teens rate (approximately 15% year-over-year), aligning with management guidance, although no acceleration was noted [2] - **Operating Margin**: Continued pressure on operating margins, primarily due to an unfavorable mix with a rising share of lower-margin SMO services [2] - **Client Mix**: MNCs now account for about 30% of new orders, domestic large pharma close to 20%, and small biotech at 32%, down from over 50% previously [2] Investor Sentiment - Investors express cautious optimism about the biotech sector but remain hesitant to increase exposure until clearer signs of recovery emerge [3] - Concerns include expected impairment charges persisting into 4Q and perceptions of Tigermed's core-earnings valuation being relatively expensive compared to peers [3] Future Outlook - Despite challenges, growth and quality of new orders are seen as key drivers for revenue and margin improvement over the next 2-3 years [18] - The company is expected to benefit from a recovery in industry pricing in early 2026 as consolidation progresses [18] - The current valuation reflects bottoming margins, which are anticipated to normalize in 2-3 years, supported by higher clinical trial volumes and pricing recovery [18] Revenue Projections - Revenue is expected to post a 15% CAGR from 2025 to 2027, supported by net new orders growing at a mid-teens rate [19][20] - **Revenue Forecasts**: - 2024: Rmb 6,603.1 million - 2025: Rmb 6,797.4 million - 2026: Rmb 7,841.7 million - 2027: Rmb 9,007.7 million [6] Risks and Challenges - Potential risks include geopolitical factors, ongoing order impairments, and slower-than-expected global expansion [31] - The company is navigating a challenging environment with legacy low-price orders and a less favorable business mix [18] Investment Thesis - Tigermed is positioned as a market leader in China's CRO sector, with extensive project execution experience and full-spectrum R&D service capabilities [32] - The company is deepening its global footprint and enhancing service capabilities, which is expected to support long-term growth and margin resilience [32] Conclusion - Tigermed remains a compelling investment opportunity with a Buy rating, driven by robust new order momentum and improving client mix, despite current market challenges and investor caution [1][32]

Investment Rating - The report assigns an "Outperform" rating to Hangzhou Tigermed Consulting, indicating a positive outlook for the company's stock performance relative to the market [4][8]. Core Insights - The report highlights a recovery in performance driven by fair value net gains, with a sequential improvement in profits for the third quarter. The company is expected to benefit from a recovery in domestic demand and further supply clearance in the CRO sector, which may lead to an increase in order prices [4][8]. - Revenue forecasts for 2025-2027 are projected at 6.51 billion RMB, 7.07 billion RMB, and 7.82 billion RMB, with growth rates of -1.4%, 8.5%, and 10.7% respectively. Net profit attributable to shareholders is expected to be 1.26 billion RMB, 1.55 billion RMB, and 1.81 billion RMB, reflecting growth rates of 209.8%, 23.4%, and 17.0% [4][8]. Financial Summary - For Q3 2025, the company reported revenue of 1.78 billion RMB, a year-on-year increase of 3.86% and a quarter-on-quarter increase of 5.29%. The net profit attributable to shareholders was 637 million RMB, showing a year-on-year increase of 98.73% and a quarter-on-quarter increase of 192.42% [4][8]. - The report notes that profit recovery was primarily due to investment income and net gains from fair value changes, contributing 207 million RMB and 413 million RMB respectively [4][8]. Business Segments - The overseas clinical operations segment is experiencing rapid growth, with expectations for significant new order contributions in the second half of 2025. However, domestic clinical operations are facing challenges due to competitive pricing and order cancellations, although a gradual recovery is anticipated as low-price orders clear [4][8]. - The SMO business has shown good year-on-year growth, driven by demand from multinational pharmaceutical companies. Other segments, such as data management and statistical analysis, remain stable, while laboratory services have seen a slight decline due to intensified competition [4][8].

Core Viewpoint - Tiger Med's stock price has experienced a decline of 5.53% year-to-date, with a significant drop of 13.21% over the past five trading days, indicating potential concerns among investors regarding the company's performance and market position [1]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, reflecting a year-on-year decrease of 0.82%. However, the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 20, Tiger Med's stock was trading at 51.32 yuan per share, with a market capitalization of 44.188 billion yuan. The stock has seen a trading volume of 264 million yuan and a turnover rate of 0.90% [1]. - The net outflow of main funds was 22.6355 million yuan, with large orders showing a buy of 466.036 million yuan and a sell of 688.923 million yuan, indicating a higher selling pressure [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The top circulating shareholder is Hong Kong Central Clearing Limited, holding 48.3625 million shares, an increase of 25.0969 million shares from the previous period [2][3].

Core Viewpoint - The announcement from Tigermed indicates that the share reduction plan by the general manager, Cao Xiaochun, has been completed, with a total of 347,600 shares reduced, which is significantly lower than the original upper limit of the plan [1] Summary by Relevant Sections - **Share Reduction Details** - Cao Xiaochun, a major shareholder and general manager, completed a share reduction plan, selling a total of 347,600 shares, which represents 0.0475% of the company's total A-share capital [1] - The reduction period has ended as of November 18, and the total shares sold are well below the planned upper limit [1] - **Impact on Company Control and Governance** - The company stated that this share reduction will not lead to any change in control and will not affect the governance structure or the ongoing operations of the company [1] - **Company Background** - Tigermed was listed on the Shenzhen Stock Exchange on August 17, 2012, and is one of the earliest CRO companies to be listed in China [1] - The company also completed a secondary listing on the Hong Kong Stock Exchange in 2020 [1]

Core Viewpoint - The announcement from Tigermed (300347) indicates that the share reduction plan by General Manager Cao Xiaochun has been completed, with a total of 347,600 shares reduced, which is significantly below the upper limit of the original plan [1] Summary by Relevant Sections Share Reduction Details - Cao Xiaochun, a major shareholder and General Manager, completed the share reduction plan on November 18, reducing a total of 347,600 shares, which accounts for 0.0475% of the company's total A-share capital [1] - The reduction was well within the limits set by the original plan, indicating a controlled approach to share divestment [1] Impact on Company Structure - The company stated that this share reduction will not lead to any change in control and will not affect the governance structure or the ongoing operations of the company [1] Company Background - Tigermed was listed on the Shenzhen Stock Exchange on August 17, 2012, and is one of the earliest listed CRO (Contract Research Organization) companies in China [1] - In 2020, the company also completed a secondary listing on the main board of the Hong Kong Stock Exchange [1]

| 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 份數目 | | | (請參閱上述*註解)有投票權股 (日 / 月 / 年) | | | | | | | | | 份百分比 | | | CS20251118E00015 | 兴证全球基金管理有限公司 | 1201(L) | | 935,900(L | HKD 41.5596 | 6.739.600(L) | 5.47(L)17/11/2025 | 泰格医药(3347.HK)今日盘中一度跌3.57%至39.44港元，股价创7月9日以来逾4个月新低。该股自上周五(11月14日)迄今已连续4个交易日下跌，累跌12.94%。 消息面上，联交所最新权益披露资料显示，泰格医药于11月17日遭兴证全球基金管理有限公司在场内以每股均价41.5596港元减持93.59万股，涉资约3889.56 万港元。减持后，其最新持股数目为673.96万股， ...